Monte Rosa Therapeutics (GLUE) EBIT (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly EBIT came in at -$50.0 million in Q1 2026, down 213.62% year-on-year from $44.0 million in Q1 2025, and down 0.64% quarter-over-quarter from -$49.7 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) EBIT (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- On a quarterly basis, EBIT fell 213.62% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$148.3 million, a 6864.68% decrease from a year earlier, with the FY2025 full-year figure at -$54.2 million, up 33.17% from the prior year.
- EBIT retreated to -$50.0 million in Q1 2026 per GLUE's latest filing, from -$49.7 million in the prior quarter.
- Across five years, EBIT topped out at $44.0 million in Q1 2025 and bottomed at -$50.0 million in Q1 2026.
- The 5-year median for EBIT is -$32.6 million (2024), against an average of -$25.9 million.
- Biggest YoY gain for EBIT was 226.01% in 2025; the steepest drop was 482.31% in 2025.
- Year by year, EBIT stood at -$32.5 million in 2022, then decreased by 7.31% to -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then tumbled by 482.31% to -$49.7 million in 2025, then decreased by 0.64% to -$50.0 million in 2026.
- Per Business Quant, the three latest GLUE EBIT figures stand at -$50.0 million (Q1 2026), -$49.7 million (Q4 2025), and -$33.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -50.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.03 Mn |
| Dec 31, 2025 | -49.72 Mn |
| Sep 30, 2025 | -32.98 Mn |
| Jun 30, 2025 | -15.55 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 13.00 Mn |
| Sep 30, 2024 | -26.53 Mn |
| Jun 30, 2024 | -32.64 Mn |
| Mar 31, 2024 | -34.95 Mn |
| Dec 31, 2023 | -34.86 Mn |
| Sep 30, 2023 | -36.97 Mn |
| Jun 30, 2023 | -37.22 Mn |
| Mar 31, 2023 | -34.26 Mn |
| Dec 31, 2022 | -32.49 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Jun 30, 2022 | -27.23 Mn |
| Mar 31, 2022 | -24.30 Mn |
| Dec 31, 2021 | -23.39 Mn |
| Sep 30, 2021 | -19.87 Mn |
| Jun 30, 2021 | -18.12 Mn |